Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

40 results about "Clostridium difficile (bacteria)" patented technology

Clostridium difficile is a species of bacteria. It is often called C. diff (pronounced "see diff"). It is a gram-positive bacteria which belongs to the genus Clostridium. C. diff can live in the human colon (the large intestine) without causing any problems.

Clostridium difficile multi-locus genotyping detection kit and application thereof

The present application belongs to the technical field of bacterial detection, and particularly relates to a Clostridium difficile multi-locus genotyping detection kit and application thereof. The present application aims to provide a new method to directly type a main Clostridium difficile strain sequence type (ST). The technical scheme of the present application is a multiplex fluorescence PCR primer set and probe for Clostridium difficile multi-locus genotyping detection, wherein the primer and probe are shown in Seq ID No. 1-18. The present application discloses a multiplex fluorescence PCR reagent for 7 main ST types of Clostridium difficile based on a fluorescence PCR-dissolution curve method. The reagent can simultaneously detect 7 main ST types of Clostridium difficile in the same PCR reaction system.
Owner:YUNNAN PROVINCIAL CENT FOR DISEASE CONTROL & PREVENTION

Pathogenic bacteria

ActiveUS12171734B2Organic active ingredientsAntibacterial agentsClostridium difficile (bacteria)Antibiotic drug
The present invention relates to pathogenic bacteria, and is particularly concerned with treating, preventing or ameliorating bacterial infections using novel antibiotic compositions. The invention is especially useful for treating infections of Bacillus and Clostridia species, such as Clostridium difficile, Staphylococcus aureus and Mycobacterium spp. The invention extends to pharmaceutical compositions comprising such formulations. The invention also extends to methods for identifying aerobic Bacillus spp., which exhibit antibacterial activity against other bacteria, such as C. difficile, and to methods for isolating active antibacterial compositions from these aerobic Bacillus spp.
Owner:SPOREGEN

Primer and probe combination, kit and method for detecting gastrointestinal pathogenic bacteria

The invention relates to a primer and probe combination, a kit and a method for detecting gastrointestinal tract pathogenic bacteria. The gastrointestinal pathogenic bacteria comprise vibrio cholerae, vibrio parahaemolyticus, salmonella, shigella, diarrheagenic escherichia coli, campylobacter, yersinia enterocolons, clostridium difficile, cronobacter sakazakii, aeromonas hydrophila, plesiomonas shigelloides and vibrio fluvialis. The primer and the probe group can be independently used for PCR amplification detection and can be combined in the same reaction system and reaction procedure for multiple PCR amplification detection, and the primers and the probes aiming at different pathogenic bacteria cannot interfere with each other during multiple PCR amplification detection. The primer and probe combination covers various types of gastrointestinal pathogenic bacteria, and is high in sensitivity, low in detection limit, good in specificity and wide in application prospect.
Owner:GUANGZHOU WONDFO BIOTECH

Monoclonal antibody-containing composition for suppressing clostridium difficile bacteria

The present invention relates to a composition comprising a monoclonal antibody binding to Clostridium difficile (C. difficile) for inhibiting a growth of Clostridium difficile (C. difficile), and a use thereof. In addition, the present invention discloses the composition for treating an inflammatory bowel disease, and a use thereof.
Owner:THE UNIV OF TOKYO

Clostridium difficile infection-related intestinal flora marker and application thereof

The invention discloses an intestinal flora marker related to clostridium difficile infection and an application of the intestinal flora marker. The intestinal flora marker is prepared from clostridium lakrakii, fusobacterium and clostridioids, and is characterized in that the intestinal flora marker is prepared from clostridium lakrakii, fusobacterium fusobacterium and clostridioids, and the clostridium lakrakii, the fusobacterium fusobacterium and the clostridioids are added into the clostridium difficile and the clostridium difficile and the clostridium difficile and the clostridium difficile and the clostridium difficile. The invention discovers that the three intestinal bacteria are related to clostridium difficile infection for the first time, and when the three bacteria are combined as a detection marker to predict clostridium difficile infection, the accuracy is high, and the detection mode is noninvasive. The invention provides a new way and tool for diagnosis of clostridium difficile infected patients.
Owner:RENMIN HOSPITAL OF WUHAN UNIVERSITY (HUBEI GENERAL HOSPITAL) +1

Primer group for simultaneously detecting four types of horse digestive tract bacteria and application of primer group

The invention discloses a primer group for simultaneously detecting four equine digestive tract bacteria and application thereof, the primer group comprises primer sequences as shown in SEQ ID NO: 1-8, and the four equine digestive tract bacteria are salmonella enteritidis, salmonella typhimurium, clostridium difficile and lawsonia intracellular. Extracting total DNA (deoxyribonucleic acid) of a sample to be detected by using the excrement sample nucleic acid extraction kit; the total DNA is used as a template, and the primer group is used for multiple PCR reaction to obtain an amplification curve. According to the invention, a primer sequence with high sensitivity and specificity is adopted, so that the quality of a detection result is ensured; the detection method is simple to operate, time-saving and labor-saving; the detection flux is high, and the reagent consumable cost is low.
Owner:NANJING ZHUOYI BIOTECHNOLOGY CO LTD

Agents for the treatment of non-replicating bacteria

PCT designated stage expiredWO2025049804A3Peptide/protein ingredientsPeptidesDiseaseBacillus cereus
In one aspect, the invention relates to compounds useful as hybrid antibiotics, acting as both activators of the ClpP protease and inhibitors of RNA polymerase activity. Also disclosed are methods of using the disclosed compounds in the treatment of infectious diseases such as, for example, biofilm-mediated diseases and infectious diseases due to prosthetic joint infections, intracellular bacteria, and Gram-positive bacteria (e.g., Gram-positive bacteria selected from Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Clostridium difficile, Clostridium tetani, Clostridium botulinum, Clostridium perfringens, Corynebacterium diphtheria, Enterococcus faecalis, Enterococcus faecium, Listeria monocytogenes, Listeria ivanovii, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus hyicus, Staphylococcus intermedius, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC +1

Stable vaccine against Clostridium difficile

The present invention relates to a synthetic saccharide of general formulate (I) that is related to Clostridium difficile PS-II cell-surface polysaccharide and conjugate thereof. Said synthetic saccharide, said conjugate and pharmaceutical composition containing said synthetic saccharide or said conjugate are useful for prevention and / or treatment of diseases associated with Clostridium difficile. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Clostridium difficile bacteria.
Owner:IDORSIA PHARMACEUTICALS LTD

Non-protein metabolite of Thailand enterococcus d5B, application of non-protein metabolite and anti-clostridium difficile antibacterial composition

The invention provides a non-protein metabolite of Thailand enterococcus d5B and application of the non-protein metabolite. The non-protein metabolite of the Thailand enterococcus d5B is a product obtained after enzymolysis of cell-free supernate of the Thailand enterococcus d5B by protease; the collection number of Thailand enterococcus d5B is CCTCC (China Center for Type Culture Collection) NO: M 20232279, and the Thailand enterococcus d5B is collected in the China Center for Type Culture Collection on November 20, 2023. The inventor discovers that the non-protein metabolite of the Thailand enterococcus d5B can play a role in killing clostridium difficile in a concentration-dependent manner, a good antibacterial effect can be achieved when the concentration of CFS containing the non-protein metabolite is 1 mu g / mu L or above, and the CFS containing the non-protein metabolite is an effective clostridium difficile bacteriostatic active component; the non-protein metabolite of the Thailand enterococcus has the antibacterial effect on the clostridium difficile for the first time at home and abroad, and has extremely high application value in the aspect of clinical treatment.
Owner:SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE

Agents for the treatment of non-replicating bacteria

PCT designated stage expiredWO2025049804A2PeptidesCyclic peptide ingredientsDiseaseBacillus cereus
In one aspect, the invention relates to compounds useful as hybrid antibiotics, acting as both activators of the ClpP protease and inhibitors of RNA polymerase activity. Also disclosed are methods of using the disclosed compounds in the treatment of infectious diseases such as, for example, biofilm-mediated diseases and infectious diseases due to prosthetic joint infections, intracellular bacteria, and Gram-positive bacteria (e.g., Gram-positive bacteria selected from Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Clostridium difficile, Clostridium tetani, Clostridium botulinum, Clostridium perfringens, Corynebacterium diphtheria, Enterococcus faecalis, Enterococcus faecium, Listeria monocytogenes, Listeria ivanovii, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus hyicus, Staphylococcus intermedius, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC +1

Diluent for detecting clostridium difficile in excrement sample and application thereof

The invention belongs to the technical field of pathogenic bacterium detection, and particularly discloses a diluent for detecting clostridium difficile in an excrement sample and application of the diluent. The diluent for detecting the clostridium difficile in the excrement sample is prepared from fetal calf serum, bovine serum albumin, a detergent and an anti-interference agent according to a specific proportion. Wherein efficient extraction and detection of the clostridium difficile GDH are realized through broad-spectrum protection of the FBS, directional stabilization of the BSA, formation of a multi-layer protection network through the FBS-BSA, targeted splitting decomposition of the detergent and specific removal of the anti-interference agent. According to the invention, the relation among the splitting efficiency, enzyme protection and interference elimination is balanced by precisely regulating and controlling the proportion of the related components, and a reliable technical scheme is provided for clinical rapid diagnosis of clostridium difficile. The kit provided based on the diluent has the advantages of being good in stability, high in accuracy, low in cost, convenient to use and the like, and the clostridium difficile in an excrement sample can be efficiently and rapidly detected by adopting the kit.
Owner:SHIJIAZHUANG HIPRO BIOTECH

Lactobacillus rhamnosus A21173 capable of inhibiting infection of multi-drug-resistant strains and clostridium difficile, resisting oxidation, resisting aging, prolonging life and improving cognition as well as product and application of lactobacillus rhamnosus A21173

The invention discloses a lactobacillus rhamnosus A21174 for inhibiting infection of multiple drug-resistant strains and clostridium difficile and application of the lactobacillus rhamnosus A21174. The lactobacillus rhamnosus A21174 has an obvious inhibiting effect on drug-resistant staphylococcus aureus, pseudomonas aeruginosa, drug-resistant escherichia coli, drug-resistant acinetobacter baumannii and clostridium difficile type strains. Compared with a commercial strain # imgabs0 # lactobacillus rhamnosus, the lactobacillus rhamnosus A21173 disclosed by the invention has a better antibacterial effect on clostridium difficile. The lactobacillus rhamnosus A21174 also shows good effects in in-vivo and in-vitro experiments such as artificial gastrointestinal fluid resistance, cholate resistance, aging resistance, life prolonging, oxidation resistance, cognition improvement and the like, so that the strain can be used as a probiotic agent for preparing a product for regulating intestinal flora, and has a good application prospect. The invention has important significance for preventing and / or treating diseases caused by multidrug-resistant bacterium infection, clostridium difficile and pseudomonas aeruginosa infection.
Owner:AIAGE LIFE SCI CORP LTD

Primer group for detecting seven pet enteropathogenic bacteria and application thereof

The invention discloses a primer group for simultaneously detecting seven pet enteropathogenic bacteria and application thereof, the primer group comprises primer sequences as shown in SEQ ID NO: 1-14, and the seven pet enteropathogenic bacteria are hemorrhagic escherichia coli, salmonella enteritidis, campylobacter jejuni, clostridium difficile, clostridium perfringens, yersinia enteritidis and staphylococcus aureus. Extracting DNA (Deoxyribonucleic Acid) of a sample to be detected by using the excrement sample nucleic acid extraction kit; taking the sample DNA as a template, carrying out multiple PCR reaction by using the primer group to obtain an amplification curve, and if the Ct value of the amplification curve of the sample to be detected is 0 amp, detecting the Ct value of the sample to be detected; lt; c < tamp >; lt; 30, and the Ct value of the IPC is amp; lt; and 40, determining that the interpretation result is positive, and indicating that the sample to be detected contains the one or more enteropathogenic bacteria. According to the invention, a primer sequence with high sensitivity and specificity is adopted, so that the quality of a detection result is ensured; the detection method is simple to operate, time-saving and labor-saving; the detection flux is high, and the reagent consumable cost is low.
Owner:NANJING ZHUOYI BIOTECHNOLOGY CO LTD

Glycopeptide antibiotic combination therapy

Bacterial infections evading the current antibiotic arsenal warrant new treatment options. The mainstay treatment for Clostridium difficile infections involves administration of the broad-spectrum antibiotic vancomycin, which also depletes the gut microbiome and its natural defenses. This leads to recurrent C. difficile infections in 20-30% of patients. Alternative treatment options are limited, triggering a perpetual cycle of relapse and recovery that may eventually lead to death. Keratinicyclin B represents a glycopeptide antibiotic chemotype with a mechanism of action that is selective for Clostridia. When combined, vancomycin (or other glycopeptide antibiotic) and keratinicyclin B interact synergistically to inhibit the growth of C. difficile at concentrations far lower than their respective minimal inhibitory concentrations. Such a combination therapy could allow for targeted colonization clearance at low antibiotic doses, thereby minimizing toxicity and reducing the likelihood of relapse.
Owner:EMORY UNIVERSITY +1

Feceobacter przewalskii strain CNCM I-4573 for treatment and prevention of clostridium difficile infection

PendingCN120957735AAntibacterial agentsUnknown materialsClostridium difficile infectionsFaecalibacterium prausnitzii
The present invention relates to a bacterial strain of the species Fecalibacterium prausnitzii, which has been preserved in CNCM with a preservation number CNCM I-4573, and / or a culture supernatant thereof, for use in the treatment and / or prevention of a Clostridium difficile infection in an individual. The present invention also relates to a method for producing the bacterial strain of the species Fecalibacterium prausnitzii, and to a method for producing the bacterial strain of the species Fecalibacterium prausnitzii, which has been preserved in CNCM with a preservation number CNCM I-4573.
Owner:EXELIOM BIOSCIENCES +5

Multiplex panel for detecting viral, bacterial, and parasitic nucleic acids

PCT designated stage expiredWO2025090839A1Microbiological testing/measurementMaterial analysisClostridium difficile (bacteria)Listeria monocytogenes
Described herein are compositions, methods, and kits for detecting diarrhea causing pathogens from patient, food, or environmental samples. One embodiment described herein is primer pairs and probes for multiplex polymerase chain reaction (PCR) based assays for the detection of gastrointestinal pathogens, such as Adenovirus, Astrovirus, Rotavirus, Norovirus, Sapovirus, Campylobacter species, Clostridium difficile, Enteroaggregative E. coli (EAEC), Enteropathogenic E. coli (EPEC), Enterotoxigenic E. coli (ETEC), Shiga-like toxin-producing E. coli (STEC), Shigella / Enteroinvasive E. coli (EIEC), E. coli O157, Listeria monocytogenes, Plesiomonas shigelloides, Salmonella species, Yersinia enterocolitica, Vibrio species, Cryptosporidium species, Cyclospora cayetanensis, Entamoeba histolytica, Giardia intestinalis, or Giardia lamblia. Other embodiments include methods and kits for detecting gastrointestinal pathogens.
Owner:LIFE TECHNOLOGIES CORP

Bifidobacterium pseudocatenum strain B24790 with functions of inhibiting clinical multi-drug-resistant bacteria and resisting inflammation and application of bifidobacterium pseudocatenum strain B24790

The invention provides a Bifidobacterium pseudocatenatum (Bifidobacterium pseudocatenatum) strain B24790 with the functions of inhibiting clinical multi-drug-resistant bacteria and resisting inflammation and application of the Bifidobacterium pseudocatenatum strain B24790, and belongs to the technical field of functional microorganisms. The invention discloses a bifidobacterium pseudocatenum strain B24790, and the preservation number of the bifidobacterium pseudocatenum strain B24790 is GDMCC No: 65515. The strain B24790 has good bacteriostatic activity on clinical multi-drug-resistant pathogenic bacteria such as clostridium difficile, acinetobacter baumannii HRAB-85, drug-resistant staphylococcus aureus, drug-resistant escherichia coli and pseudomonas aeruginosa PAO1, and also has a good anti-inflammatory effect. The strain B24790 is human-derived, has good gastrointestinal fluid resistance, and has the potential of colonization of human bodies. The bifidobacterium pseudocatenum strain B24790 provided by the invention has certain advantages in the aspects of drug-resistant bacterium infection and inflammatory diseases, can be used for preparing related products, and has a wide market prospect.
Owner:AIAGE LIFE SCI CORP LTD +1

Lactobacillus paracasei W1 and application thereof in inhibition of clostridium difficile infection

The invention discloses a strain of lactobacillus paracasei W1 and application of the strain of lactobacillus paracasei W1 in inhibiting infection of clostridium difficile, and relates to the technical field of probiotic application, and the technical key point is that the preservation number of the lactobacillus paracasei W1 is CCTCC (China Center for Type Culture Collection) M 2024619, the preservation number of the lactobacillus paracasei W1 is CCTCC M 2024619, the preservation number of the lactobacillus paracasei W1 is CCTCC M 2024619, the preservation number of the lactobacillus paracasei W1 is CCTCC M 2024619, and the preservation number of the lactobacillus paracasei W1 is CCTCC M 2024619. The lactobacillus paracasei W1 has the capability of resisting low pH of gastrointestinal tracts and high-concentration bile salt, and the sterile fermentation supernatant of the lactobacillus paracasei W1 can inhibit the growth of clostridium difficile and the formation of a biological membrane. Animal experiments show that the lactobacillus paracasei W1 can inhibit colonization of clostridium difficile in vivo, improve injury of colonic mucosa, relieve shortening of colon and relieve inflammation caused by infection of the clostridium difficile. The bacterial strain has a wide application prospect in prevention and treatment of intestinal diseases caused by infection of C. difficile, as well as related dairy products, functional products and health-care products.
Owner:CHONGQING MEDICAL UNIVERSITY +1

Enteric capsule containing corynebacterium fenfen

PendingCN118924694Aimprove securityImprove diarrhea symptomsPowder deliveryBacteriaClostridium difficile (bacteria)Bacterosira
The invention belongs to the field of living biological medicines, and particularly relates to an enteric capsule containing corynebacterium fenfen. The Afine-1 has no virulence gene, does not hemolysis in vitro, is sensitive to various antibiotics and has good safety, and the strain has obvious bacteriostatic ability to clostridium difficile; according to the enteric capsule, diarrhea induced by chemotherapeutic drugs 5-fluorouracil and irinotecan can be remarkably improved, the enteric capsule has an anti-inflammatory effect, and viable bacteria have a good gastric acid resistance function by filling the water absorbent in the bacterial powder. The enteric capsule containing the corynebacterium fenfen provided by the invention provides a new choice for preventing or treating chemotherapy-related diarrhea.
Owner:SICHUAN ANAEROBIC BIOTECHNOLOGY CO LTD

Device, procedure and system for detecting bacterial pathogens including methicillin-resistant Staphylococcus aureus or clostridium difficile

A bio-sensor device for the electrochemical detection of a bacterial pathogen, the device including a sample chamber and an electronic data module. The sample chamber includes passive sensing probes to detect pathogenic antigens in a sample containing the bacterial pathogen. The probes detect a reaction voltage corresponding to an antigen-antibody reaction occurring when the pathogenic antigens come into contact with an antibody specific for pathogenic antigens present in in the contents of the sample chamber and contacted by the electrical probes. The electronic data module detects and processes electrical signals detected by the conductive electrical probes corresponding to an amount of the antigen present in the sample, wherein the reaction voltage is detected at the time of the reaction.
Owner:KERN III CLIFFORD H +3

Clostridium difficile specimen anti-pollution treatment device

The invention relates to the technical field of clostridium difficile anti-pollution treatment, in particular to a clostridium difficile specimen anti-pollution treatment device which comprises an inoculation assembly, the top of a base of the inoculation assembly is connected with a conveying belt, and a plurality of detachable culture dishes can be placed on the conveying belt. A first supporting rod on the base is rotationally connected with a disc which fixes a bacterial liquid box through a connecting rod. And a sliding rod on the inner side of the limiting block is connected with a U-shaped fork and is in sliding fit with the circular column. The double-end driving piece is installed on the second supporting rod, an output shaft of the double-end driving piece is connected with the first L-shaped rod and the second L-shaped rod, and the first L-shaped rod is in running fit with the U-shaped fork. The second L-shaped rod is provided with an air exchange assembly which can exchange air above the culture dish. A liquid dropping assembly and a coating assembly are arranged on a circular column on the connecting rod, so that bacterium liquid dropping and coating operation can be completed. According to the clostridium difficile specimen anti-pollution treatment device, efficient inoculation and coating of clostridium difficile specimens can be achieved, the pollution risk is effectively reduced, and the detection accuracy is improved.
Owner:XIANGYA HOSPITAL CENT SOUTH UNIV

Strain for preventing and treating diarrhea caused by clostridium difficile infection and application thereof

PendingCN120591120AAntibacterial agentsFungiDiarrhea symptomsAntibiosis
The invention discloses a bacterial strain for preventing and treating diarrhea caused by clostridium difficile infection and application of the bacterial strain. The bacterial strain is saccharomyces boulardii HS5 and is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC NO.31317. The invention further discloses a preparation method of the bacterial strain for preventing and treating diarrhea caused by clostridium difficile infection and application of the bacterial strain for preventing and treating diarrhea caused by clostridium difficile infection. The preservation time is October 11, 2021; the bacterial strain for preventing and treating diarrhea caused by clostridium difficile infection is obtained through screening, the bacterial strain can remarkably inhibit growth of clostridium difficile, has excellent antibacterial performance on clostridium difficile, can further prevent and improve diarrhea symptoms caused by clostridium difficile infection, and is quick in effect and remarkable in effect.
Owner:SHANGHAI HELPLIFES TECH CO LTD

Antibodies binding to clostridium difficile

The inventors of the present disclosure have undergone in-depth studies and found that an antibody that binds to and inhibits the proliferation of intestinal bacteria, particularly clostridium difficile cells and other intestinal bacteria cells. The present disclosure exerts the effect of providing antibodies and antigen-binding fragments thereof that bind to enteral bacteria, in particular, clostridium difficile and other enteral bacteria, and uses thereof.
Owner:THE UNIV OF TOKYO

Clostridium difficile multi-component vaccine

InactiveJP2024175058A
To provide an immunogenic composition, a method for producing a vaccine, and a method for administering a vaccine.SOLUTION: An immunogenic composition comprises: (a) inactivated whole cells of one or more strains of C. difficile bacteria, or a cell surface extract (CSE) from one or more strains of C. difficile bacteria, and (b) at least one polypeptide comprising a toxoid or a non-toxic immunogenic polypeptide fragment of a C. difficile Toxin A or Toxin B, wherein the composition, when administered to a mammalian subject, is effective to elicit production of antibodies recognizing a wild type C. difficile and production of antibodies recognizing at least one C. difficile toxin that confers protection against C. difficile infection and / or reinfection (recurrence).SELECTED DRAWING: Figure 1
Owner:MATRIBACS INC

Network-based microbial compositions and methods

InactiveJP2024167277ABacteriaMetabolism disorderBowels diseasesClostridium difficile (bacteria)
To provide methods for treating, preventing, or reducing the severity of a disorder selected from the group consisting of Clostridium difficile Associated Diarrhea (CDAD), Type 2 Diabetes, Obesity, Irritable Bowel Disease (IBD), colonization with a pathogen or pathobiont, and infection with a drug-resistant pathogen or pathobiont.SOLUTION: The present invention provides a method that includes administering an effective amount of a therapeutic composition containing a plurality of isolated bacteria or purified bacterial preparation capable of forming a network ecology to a mammalian subject in need thereof.SELECTED DRAWING: Figure 19
Owner:SERES THERAPEUTICS INC

HMO mixture and its use in reducing c. difficile toxins

PCT designated stageWO2025176780A1Hydroxy compound active ingredientsFood scienceBiotechnologyClostridial toxin
The present disclosure relates to a mixture of HMOs with at least 85 wt% of LNFP-I, 2'FL and 3'SL of the total amount of HMOs in the mixture and the use of such a mixture to decrease Clostridium difficile and its toxins in a subject. Furthermore, the mixture of HMOs can increase microbial taxa that are diminished with aging in a mammal, including increasing Bifidobacteria such Bifidobacterium longum and / or Bifidobacterium adolescentis and Faecalibacterium such as Faecalibacterium prausnitzii in the gut of a subject, in particular an elderly.
Owner:DSM IP ASSETS BV

Allocholic acid derivative with antibacterial activity and pharmaceutical composition thereof

The present invention provides an allocholic acid derivative having antibacterial activity and a pharmaceutical composition thereof, belonging to the field of medical technology. The allocholic acid derivative is a compound represented by formula (I), or a stereoisomer thereof, or a salt thereof, or a solvate thereof, or a prodrug thereof, or a metabolite thereof. This type of compound can effectively inhibit the growth of Clostridium difficile bacteria, has significant antibacterial activity, and has very good application prospects in the preparation of drugs for preventing and / or treating Clostridium difficile infectious diseases, recurrence of Clostridium difficile infectious diseases, or complications of Clostridium difficile infectious diseases.
Owner:CHENGDU BIOBEL BIOTECHNOLOGY CO LTD